2015
Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma
Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal Of Cancer 2015, 113: 1003-1009. PMID: 26393887, PMCID: PMC4651124, DOI: 10.1038/bjc.2015.308.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBone NeoplasmsBreast NeoplasmsEarly Detection of CancerFemaleHumansMiddle AgedNomogramsProportional Hazards ModelsRetrospective StudiesYoung AdultConceptsNon-metastatic breast cancerBreast cancerClinical nomogramCox proportional hazards regression modelProportional hazards regression modelsBone-targeted therapiesHormone receptor statusEarly breast cancerLymph node statusLymphovascular space invasionEarly breast carcinomaAnalysis of patientsHazards regression modelsPathologic variablesReceptor statusDistant metastasisTumor characteristicsNode statusSpace invasionT classificationPatient populationMedical recordsBreast carcinomaCommon siteConcordance index
2012
Agreement in Risk Prediction Between the 21‐Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early‐Stage Estrogen Receptor–Positive Breast Cancer
Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L. Agreement in Risk Prediction Between the 21‐Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early‐Stage Estrogen Receptor–Positive Breast Cancer. The Oncologist 2012, 17: 492-498. PMID: 22418568, PMCID: PMC3336833, DOI: 10.1634/theoncologist.2012-0007.Peer-Reviewed Original ResearchConceptsBreast cancerEstrogen receptorEarly-stage estrogen receptor-positive breast cancerRisk assignmentHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionEstrogen receptor-positive breast cancerReceptor-positive breast cancerIntermediate RS groupLuminal B cancersReceptor 2 expressionLow-risk categoryQuantitative polymerase chain reactionB cancersMore patientsPolymerase chain reactionIntermediate RSLower riskStage IRS groupCancerPAM50Risk categoriesRisk predictionChain reaction